Chronic Heart Failure Drug Development Using Patient-Centric Chip Platform with Ayla Annac InvivoSciences

Published: Aug. 4, 2020, 3:41 p.m.

Ayla Annac, CEO and Co-Founder, InvivoSciences shines light on the next generation of precision medicine and explains how IVS is personalizing the drug development process with patient-derived and gene-edited human samples.\xa0 The company's Novel Heart Tissue on a chip platform NuHeart\u2122 enables rapid identification of the safety and efficacy profile of a given treatment for a specific patient group.\xa0 IVS is saving time and money in developing new therapies while increasing the success rate of approval for cardio safe therapies.

#COVID19 #ChronicHeartFailure

InvivoSciences.com

Download the transcript here

\xa0